Document Detail


Controlled trial of pergolide mesylate in Parkinson's disease and progressive supranuclear palsy.
MedLine Citation:
PMID:  6339985     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We evaluated pergolide in 22 patients with Parkinson's disease and 3 with progressive supranuclear palsy (PSP). After achieving an optimal dose of pergolide and Sinemet, a matching placebo was substituted in double-blind manner. The mean dose of levodopa (in Sinemet) was reduced by 68%; in eight patients, pergolide completely replaced levodopa. In parkinsonian patients, the mean Hoehn-Yahr stage decreased from 3.2 to 1.6, and the mean total disability score decreased from 48.3 to 17.8. In 10 patients with on-off phenomenon, the time on increased 174% with pergolide. There was little effect in PSP. Postural light-headedness and reversible mental changes were seen.
Authors:
J Jankovic
Related Documents :
22863575 - The link between enthesitis and arthritis in psoriatic arthritis: a switch to a vascula...
1866005 - Spatial contrast sensitivity is reduced in bilateral parkinson's disease.
19814775 - Is there any association between disturbed gastrointestinal visceromotor and sensory fu...
19765055 - Impairment of rapid repetitive finger movements and visual reaction time in patients wi...
25338305 - The relationship between skewed x chromosome inactivation and the prognosis of graves' ...
24372155 - Unexpectedly increased anorexigenic postprandial responses of pyy and glp-1 to fast ice...
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article    
Journal Detail:
Title:  Neurology     Volume:  33     ISSN:  0028-3878     ISO Abbreviation:  Neurology     Publication Date:  1983 Apr 
Date Detail:
Created Date:  1983-05-05     Completed Date:  1983-05-05     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0401060     Medline TA:  Neurology     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  505-7     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antiparkinson Agents / therapeutic use*
Bulbar Palsy, Progressive / drug therapy*
Clinical Trials as Topic
Double-Blind Method
Ergolines / administration & dosage,  therapeutic use*
Female
Humans
Levodopa / administration & dosage,  therapeutic use
Male
Middle Aged
Parkinson Disease / drug therapy*
Pergolide
Placebos
Chemical
Reg. No./Substance:
0/Antiparkinson Agents; 0/Ergolines; 0/Levodopa; 0/Placebos; 66104-22-1/Pergolide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Dural sinus pressure as related to neurosurgical positions.
Next Document:  Intracellular and extracellular proteins binding androgenic hormones. Biochemical properties and cli...